{
  "analysis_timestamp": "2026-01-30T18:13:11.151627",
  "analyses": {
    "benefit_factor": {
      "benefit_sub_factor": "Off label",
      "description": "Off label",
      "weight": 10,
      "score": 1,
      "weighted_score": 10,
      "score_type": "benefit",
      "cdsco_approved": false,
      "usfda_approved": false
    },
    "market_experience": {
      "experience_sub_factor": "Established indication (>5Y, approved widely)",
      "description": "Established indication (>5Y, approved widely)",
      "weight": 90,
      "score": 5,
      "weighted_score": 450,
      "score_type": "benefit",
      "years_in_market": 41
    },
    "pubmed_evidence": {
      "evidence_sub_factor": "Low evidence (limited data, uncertain)",
      "description": "Low evidence (limited data, uncertain)",
      "weight": 30,
      "score": 1,
      "weighted_score": 30,
      "score_type": "benefit",
      "rct_count": 0
    },
    "contraindication": {
      "description": "Safe - no contraindication",
      "weight": 0,
      "score": 0,
      "weighted_score": 0,
      "score_type": "risk",
      "status": "safe"
    },
    "therapeutic_duplication": {
      "status": "not_applicable",
      "reason": "Single medication for this condition - no duplication check needed"
    },
    "life_threatening_adrs": {
      "lt_adr_category": "Low Risk - No life-threatening ADRs detected",
      "description": "No life-threatening ADRs",
      "weight": 10,
      "score": 1,
      "weighted_score": 10,
      "score_type": "risk",
      "adr_count": 0,
      "has_risk_factors": false
    },
    "serious_adrs": {
      "serious_adr_category": "Low Risk - No serious ADRs detected",
      "description": "No serious ADRs / no interactions",
      "weight": 20,
      "score": 1,
      "weighted_score": 20,
      "score_type": "risk",
      "adr_count": 0,
      "has_risk_factors": false
    },
    "drug_interactions": {
      "interaction_category": "No Drug Interactions",
      "description": "No drug interactions",
      "weight": 0,
      "score": 0,
      "weighted_score": 0,
      "score_type": "risk",
      "contraindicated_count": 0,
      "lt_interaction_count": 0,
      "serious_interaction_count": 0,
      "total_critical_interactions": 0
    },
    "medical_need_severity": {
      "medical_need_category": "Acute, Life-Threatening Condition",
      "description": "Acute, life-threatening condition",
      "weight": 100,
      "score": 5,
      "weighted_score": 500,
      "score_type": "benefit",
      "severity_level": "critical",
      "is_life_threatening": true,
      "is_acute": true
    },
    "risk_mitigation_feasibility": {
      "mitigation_sub_factor": "Preventable and Reversible ADR",
      "worst_case_adr": "Manageable",
      "description": "Preventable and Reversible ADR",
      "weight": 30,
      "score": 1,
      "weighted_score": 30,
      "score_type": "risk"
    },
    "summary": {
      "drug": "Ibuprofen",
      "diagnosis": "Upper Gastrointestinal Bleeding",
      "total_weighted_score": 1050,
      "total_benefit_score": 990,
      "total_risk_score": 60,
      "brr": 16.5,
      "brr_interpretation": "Excellent - Benefits strongly outweigh risks",
      "score_breakdown": {
        "pubmed_evidence": {
          "evidence_sub_factor": "Low evidence (limited data, uncertain)",
          "description": "Low evidence (limited data, uncertain)",
          "weight": 30,
          "score": 1,
          "weighted_score": 30,
          "score_type": "benefit",
          "rct_count": 0
        },
        "contraindication_risk": {
          "description": "Safe - no contraindication",
          "weight": 0,
          "score": 0,
          "weighted_score": 0,
          "score_type": "risk",
          "status": "safe"
        }
      },
      "therapeutic_duplication_performed": false,
      "rct_count": 0,
      "has_contraindication": false,
      "has_life_threatening_adrs": false,
      "has_serious_adrs": false,
      "has_drug_interactions": false,
      "rmm": [
        {
          "medicine": "Ibuprofen",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Heart Failure",
          "section_5_warnings_and_precautions_extract": "Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart sur",
          "proactive_actions_symptoms_to_monitor": "\"Leg swelling, Trouble breathing\"",
          "immediate_actions_required": "{",
          "immediate_actions_reasoning": "\"ACTION\": \"Discontinuation with initiation of better alternatives in safety and efficacy\","
        },
        {
          "medicine": "Ibuprofen",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Stroke",
          "section_5_warnings_and_precautions_extract": "stomach ulcers or bleeding problems have 3 or more alcoholic drinks every day while using this product are age 60 or older take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others] Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke",
          "proactive_actions_symptoms_to_monitor": "\"Slurred speech, Weakness in one part or side of body\"",
          "immediate_actions_required": "{",
          "immediate_actions_reasoning": "\"ACTION\": \"Discontinuation with initiation of better alternatives in safety and efficacy\","
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Anaphylaxis",
          "section_5_warnings_and_precautions_extract": "Promptly stop ZITUVIMET, assess for other potential causes, institute appropriate monitoring and treatment",
          "proactive_actions_symptoms_to_monitor": "\"\"",
          "immediate_actions_required": "Discontinuation with initiation of better alternatives in safety and efficacy AND/OR initiation of required supplementations",
          "immediate_actions_reasoning": "Anaphylaxis is a life-threatening emergency requiring immediate intervention as per FDA guidelines."
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Stevens-Johnson Syndrome",
          "section_5_warnings_and_precautions_extract": "Promptly stop ZITUVIMET, assess for other potential causes, institute appropriate monitoring and treatment",
          "proactive_actions_symptoms_to_monitor": "\"Exfoliative skin conditions\"",
          "immediate_actions_required": "Discontinuation with initiation of better alternatives in safety and efficacy AND/OR initiation of required supplementations",
          "immediate_actions_reasoning": "Stevens-Johnson Syndrome is a life-threatening emergency requiring immediate intervention as per FDA guidelines."
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Heart Failure",
          "section_5_warnings_and_precautions_extract": "Monitor patients for signs and symptoms",
          "proactive_actions_symptoms_to_monitor": "\"\"",
          "immediate_actions_required": "{",
          "immediate_actions_reasoning": "\"ACTION\": \"Discontinuation with initiation of better alternatives in safety and efficacy\","
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Renal Failure",
          "section_5_warnings_and_precautions_extract": "Monitor patients for signs and symptoms. Before initiating ZITUVIMET and at least annually thereafter, assess renal function",
          "proactive_actions_symptoms_to_monitor": "\"\"",
          "immediate_actions_required": "{",
          "immediate_actions_reasoning": "\"ACTION\": \"Discontinuation with initiation of better alternatives in safety and efficacy\","
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Necrotizing Pancreatitis",
          "section_5_warnings_and_precautions_extract": "NA",
          "proactive_actions_symptoms_to_monitor": "\"\"",
          "immediate_actions_required": "{",
          "immediate_actions_reasoning": "\"ACTION\": \"Discontinuation with initiation of better alternatives in safety and efficacy\","
        },
        {
          "medicine": "Metformin",
          "risk_type": "LT/Fatal ADR",
          "risk_description": "Lactic Acidosis",
          "section_5_warnings_and_precautions_extract": "NA",
          "proactive_actions_symptoms_to_monitor": "\"Malaise, Myalgias (muscle pain), Abdominal pain, Increased somnolence (drowsiness), Respiratory distress (",
          "immediate_actions_required": "Discontinuation with initiation of better alternatives in safety and efficacy",
          "immediate_actions_reasoning": "Lactic Acidosis is a life-threatening emergency requiring immediate intervention as per FDA guidelines."
        }
      ],
      "consequence": {
        "date": "2026-01-30 18:12:32",
        "patient": {
          "age": 60,
          "gender": "Male",
          "condition": "Severe dizziness, black stools, and fainting",
          "diagnosis": "Upper Gastrointestinal Bleeding, Lactic Acidosis",
          "smoking_alcohol": "Not specified",
          "date_of_assessment": "2026-01-30"
        },
        "diagnoses_analyzed": [
          "Upper Gastrointestinal Bleeding",
          "Lactic Acidosis",
          "Severe dizziness",
          "black stools",
          "and fainting"
        ],
        "factor_2_6_consequences_of_non_treatment": {
          "Upper Gastrointestinal Bleeding": {
            "disease": "Upper Gastrointestinal Bleeding",
            "classifications": [
              {
                "category": "Unable to determine",
                "timeframe": "Unknown",
                "consequences_if_untreated": "Unable to analyze consequences for Upper Gastrointestinal Bleeding",
                "severity": "Unknown",
                "specific_outcomes": [],
                "reliable_sources_used": []
              }
            ]
          },
          "Lactic Acidosis": {
            "disease": "Lactic Acidosis",
            "classifications": [
              {
                "category": "Acute, life-threatening condition",
                "timeframe": "Immediate/short-term",
                "consequences_if_untreated": "Untreated lactic acidosis rapidly leads to severe metabolic derangements, impairing cellular function and organ perfusion. The profound acidosis directly depresses myocardial contractility, reduces systemic vascular resistance, and can cause refractory hypotension. It also interferes with enzyme function, oxygen delivery, and cellular metabolism across multiple organ systems. Without prompt identification and treatment of the underlying cause and correction of the acidosis, the condition progresses to multi-organ system failure.",
                "severity": "Death or irreversible organ damage",
                "specific_outcomes": [
                  "Cardiovascular collapse (refractory hypotension, arrhythmias, decreased cardiac output)",
                  "Respiratory failure (due to respiratory muscle fatigue and inability to compensate for acidosis)",
                  "Acute kidney injury (AKI)",
                  "Hepatic dysfunction",
                  "Central nervous system depression (confusion, stupor, coma)",
                  "Multi-organ system failure (MOSF)",
                  "Death"
                ],
                "reliable_sources_used": [
                  "StatPearls/NCBI/NIH",
                  "UpToDate",
                  "Johns Hopkins Medicine",
                  "Mayo Clinic"
                ]
              }
            ]
          },
          "Severe dizziness": {
            "disease": "Severe dizziness",
            "classifications": [
              {
                "category": "Unable to determine",
                "timeframe": "Unknown",
                "consequences_if_untreated": "Unable to analyze consequences for Severe dizziness",
                "severity": "Unknown",
                "specific_outcomes": [],
                "reliable_sources_used": []
              }
            ]
          },
          "black stools": {
            "disease": "black stools",
            "classifications": [
              {
                "category": "Unable to determine",
                "timeframe": "Unknown",
                "consequences_if_untreated": "Unable to analyze consequences for black stools",
                "severity": "Unknown",
                "specific_outcomes": [],
                "reliable_sources_used": []
              }
            ]
          },
          "and fainting": {
            "disease": "and fainting",
            "classifications": [
              {
                "category": "Unable to determine",
                "timeframe": "Unknown",
                "consequences_if_untreated": "Unable to analyze consequences for and fainting",
                "severity": "Unknown",
                "specific_outcomes": [],
                "reliable_sources_used": []
              }
            ]
          }
        },
        "total_diagnoses_analyzed": 5,
        "consequence_score": {
          "medical_need_category": "Acute, Life-Threatening Condition",
          "description": "Acute, life-threatening condition",
          "weight": 100,
          "score": 5,
          "weighted_score": 500,
          "score_type": "benefit",
          "severity_level": "critical",
          "is_life_threatening": true,
          "is_acute": true
        }
      },
      "rmf": {
        "date": "2026-01-30 18:13:11",
        "patient": {
          "age": 60,
          "gender": "Male",
          "condition": "Severe dizziness, black stools, and fainting",
          "diagnosis": "Upper Gastrointestinal Bleeding, Lactic Acidosis",
          "smoking_alcohol": "Not specified",
          "date_of_assessment": "2026-01-30"
        },
        "medications": [
          "Ibuprofen",
          "Metformin"
        ],
        "total_adrs_analyzed": 8,
        "factor_3_4_risk_mitigation_feasibility": {
          "risk_reversibility_risk_tolerability": {
            "Ibuprofen - Heart Failure": {
              "medicine": "Ibuprofen",
              "adr_name": "Heart Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Reversible ADR",
              "reasoning": "Heart failure induced by NSAIDs like ibuprofen is typically reversible upon drug discontinuation and appropriate medical management. The effect is often related to fluid retention and increased blood pressure, which can be reversed.",
              "fda_evidence": "Based on medical knowledge",
              "keywords_found": [
                "Heart Failure",
                "Ibuprofen"
              ]
            },
            "Ibuprofen - Stroke": {
              "medicine": "Ibuprofen",
              "adr_name": "Stroke",
              "adr_type": "LT/Fatal ADR",
              "classification": "Irreversible ADR",
              "reasoning": "Stroke can cause permanent neurological damage and long-term disability, making it an irreversible adverse drug reaction.",
              "fda_evidence": "Based on medical knowledge",
              "keywords_found": [
                "Stroke",
                "permanent damage"
              ]
            },
            "Metformin - Anaphylaxis": {
              "medicine": "Metformin",
              "adr_name": "Anaphylaxis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Reversible ADR",
              "reasoning": "Anaphylaxis, while severe, is generally reversible with prompt treatment (e.g., epinephrine, antihistamines, corticosteroids) and discontinuation of the offending medication. The FDA text advises prompt discontinuation and appropriate monitoring and treatment, implying reversibility with intervention.",
              "fda_evidence": "Promptly stop ZITUVIMET, assess for other potential causes, institute appropriate monitoring and treatment.",
              "keywords_found": [
                "anaphylaxis",
                "hypersensitivity reactions",
                "treatment"
              ]
            },
            "Metformin - Stevens-Johnson Syndrome": {
              "medicine": "Metformin",
              "adr_name": "Stevens-Johnson Syndrome",
              "adr_type": "LT/Fatal ADR",
              "classification": "Irreversible ADR",
              "reasoning": "Stevens-Johnson Syndrome is a known irreversible condition with permanent consequences",
              "fda_evidence": "Documented as irreversible in medical literature",
              "keywords_found": [
                "stevens-johnson syndrome"
              ]
            },
            "Metformin - Heart Failure": {
              "medicine": "Metformin",
              "adr_name": "Heart Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Reversible ADR",
              "reasoning": "While heart failure can be a severe condition, in the context of Metformin (specifically ZITUVIMET in this FDA document), the FDA warning suggests monitoring patients for signs and symptoms, implying that managing risk factors and discontinuation if necessary could improve or resolve the condition. This does not indicate permanent damage in all cases, making it potentially reversible.",
              "fda_evidence": "Heart Failure : Has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of ZITUVIMET in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms.",
              "keywords_found": [
                "Heart Failure",
                "Monitor",
                "risk factors"
              ]
            },
            "Metformin - Renal Failure": {
              "medicine": "Metformin",
              "adr_name": "Renal Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Reversible ADR",
              "reasoning": "The FDA USPI states that acute renal failure has been reported postmarketing, sometimes requiring dialysis, implying that renal function can potentially recover after drug discontinuation or with supportive treatment like dialysis.",
              "fda_evidence": "Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis.",
              "keywords_found": [
                "Renal Failure",
                "dialysis"
              ]
            },
            "Metformin - Necrotizing Pancreatitis": {
              "medicine": "Metformin",
              "adr_name": "Necrotizing Pancreatitis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Irreversible ADR",
              "reasoning": "Necrotizing pancreatitis involves tissue death, which may result in permanent damage to the pancreas, leading to long-term complications even after drug discontinuation.",
              "fda_evidence": "There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue ZITUVIMET.",
              "keywords_found": [
                "necrotizing pancreatitis",
                "fatal"
              ]
            },
            "Metformin - Lactic Acidosis": {
              "medicine": "Metformin",
              "adr_name": "Lactic Acidosis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Reversible ADR",
              "reasoning": "The FDA USPI states that lactic acidosis is managed by discontinuing the drug and instituting supportive measures. It does not state any permanent damage or long-term effects after such measures.",
              "fda_evidence": "If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of ZITUVIMET.",
              "keywords_found": [
                "lactic acidosis",
                "discontinuation",
                "supportive measures"
              ]
            }
          },
          "risk_preventability": {
            "Ibuprofen - Heart Failure": {
              "medicine": "Ibuprofen",
              "adr_name": "Heart Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Preventable ADR",
              "reasoning": "Ibuprofen-induced heart failure is often related to fluid retention and increased blood pressure, both of which can be exacerbated by NSAIDs. Monitoring blood pressure and fluid status, especially in patients with pre-existing cardiovascular risk factors, can help prevent this ADR. Dose adjustments or alternative pain management strategies can also be implemented.",
              "fda_evidence": "None None Directions do not take more than directed the smallest effective dose should be used adults and children 12 years and over: take 1 tablet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 tablet, 2 tablets may be used do not exceed 6 tablets in 24 hours, unless directed by a doctor children under 12 years: ask a doctor",
              "prevention_measures": [
                "Monitor blood pressure",
                "Monitor fluid status, especially in patients with pre-existing heart conditions",
                "Use the lowest effective dose for the shortest duration",
                "Consider alternative pain management strategies in high-risk patients",
                "Educate patients about symptoms of heart failure"
              ]
            },
            "Ibuprofen - Stroke": {
              "medicine": "Ibuprofen",
              "adr_name": "Stroke",
              "adr_type": "LT/Fatal ADR",
              "classification": "Preventable ADR",
              "reasoning": "While the exact mechanism by which NSAIDs like ibuprofen increase stroke risk isn't fully understood, it's associated with increased blood pressure and potential effects on platelet aggregation. The FDA labeling emphasizes using the lowest effective dose for the shortest duration, which suggests that dose and duration management can mitigate the risk. Patients with pre-existing cardiovascular conditions are at higher risk and should be carefully monitored.",
              "fda_evidence": "Directions do not take more than directed the smallest effective dose should be used",
              "prevention_measures": [
                "Use the lowest effective dose for the shortest duration",
                "Monitor blood pressure, especially in patients with hypertension or cardiovascular risk factors",
                "Consider alternative pain relievers in patients at high risk for stroke",
                "Educate patients on the signs and symptoms of stroke"
              ]
            },
            "Metformin - Anaphylaxis": {
              "medicine": "Metformin",
              "adr_name": "Anaphylaxis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Non-preventable ADR",
              "reasoning": "Anaphylaxis is an idiosyncratic/unpredictable reaction that cannot be prevented by routine monitoring",
              "fda_evidence": "Documented as unpredictable reaction",
              "prevention_measures": []
            },
            "Metformin - Stevens-Johnson Syndrome": {
              "medicine": "Metformin",
              "adr_name": "Stevens-Johnson Syndrome",
              "adr_type": "LT/Fatal ADR",
              "classification": "Non-preventable ADR",
              "reasoning": "Stevens-Johnson Syndrome is an idiosyncratic/unpredictable reaction that cannot be prevented by routine monitoring",
              "fda_evidence": "Documented as unpredictable reaction",
              "prevention_measures": []
            },
            "Metformin - Heart Failure": {
              "medicine": "Metformin",
              "adr_name": "Heart Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Preventable ADR",
              "reasoning": "The FDA warning states that heart failure has been observed with other drugs in the same class and advises considering the risks and benefits in patients with known risk factors for heart failure and monitoring patients for signs and symptoms. This implies that careful patient selection and monitoring can potentially mitigate the risk of heart failure associated with Metformin (in ZITUVIMET).",
              "fda_evidence": "Heart Failure : Has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of ZITUVIMET in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms.",
              "prevention_measures": [
                "Assess patient's risk factors for heart failure before starting Metformin.",
                "Monitor patients for signs and symptoms of heart failure during treatment."
              ]
            },
            "Metformin - Renal Failure": {
              "medicine": "Metformin",
              "adr_name": "Renal Failure",
              "adr_type": "LT/Fatal ADR",
              "classification": "Preventable ADR",
              "reasoning": "The FDA USPI highlights that acute renal failure has been reported postmarketing and recommends assessing renal function before initiating treatment and at least annually thereafter. This suggests that proactive monitoring of renal function can potentially prevent or mitigate the risk of renal failure associated with metformin use.",
              "fda_evidence": "Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Before initiating ZITUVIMET and at least annually thereafter, assess renal function.",
              "prevention_measures": [
                "Assess renal function before initiating metformin",
                "Monitor renal function at least annually during treatment",
                "Dose adjustment based on renal function",
                "Avoid concomitant use of nephrotoxic agents"
              ]
            },
            "Metformin - Necrotizing Pancreatitis": {
              "medicine": "Metformin",
              "adr_name": "Necrotizing Pancreatitis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Non-preventable ADR",
              "reasoning": "While the USPI mentions postmarketing reports of necrotizing pancreatitis and advises discontinuing the drug if suspected, it doesn't offer specific, proactive measures to prevent its occurrence. The development of pancreatitis is often unpredictable and may not be directly linked to identifiable risk factors or lab values.",
              "fda_evidence": "Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue ZITUVIMET.",
              "prevention_measures": [
                "Close monitoring for abdominal pain",
                "Prompt discontinuation upon suspicion"
              ]
            },
            "Metformin - Lactic Acidosis": {
              "medicine": "Metformin",
              "adr_name": "Lactic Acidosis",
              "adr_type": "LT/Fatal ADR",
              "classification": "Preventable ADR",
              "reasoning": "Lactic acidosis with metformin is often associated with renal impairment or other risk factors. The FDA warning highlights the importance of assessing renal function before and during treatment. Early detection of symptoms and immediate discontinuation are also emphasized, making this ADR potentially preventable through proactive monitoring and management.",
              "fda_evidence": "Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Before initiating ZITUVIMET and at least annually thereafter, assess renal function.",
              "prevention_measures": [
                "Assess renal function before and periodically during treatment",
                "Monitor for non-specific symptoms like malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence",
                "Avoid use in patients with risk factors such as renal impairment, heart failure, or dehydration",
                "Discontinue ZITUVIMET immediately if lactic acidosis is suspected"
              ]
            }
          }
        },
        "mitigation_score": {
          "mitigation_sub_factor": "Preventable and Reversible ADR",
          "worst_case_adr": "Manageable",
          "description": "Preventable and Reversible ADR",
          "weight": 30,
          "score": 1,
          "weighted_score": 30,
          "score_type": "risk"
        }
      }
    }
  },
  "benefit_risk_ratio": {
    "total_benefit_score": 990,
    "total_risk_score": 60,
    "brr": 16.5,
    "interpretation": "Excellent - Benefits strongly outweigh risks",
    "benefit_components": 4,
    "risk_components": 5
  }
}